Immunotherapy has revolutionized the treatment of cancer due to its remarkable efficacy and
extensive survival benefit in multiple tumor types. However, predictive biomarkers are …

FDA-approved next-generation sequencing assays based on cell-free DNA offers new
opportunities in a molecular-tumor-board context thanks to the noninvasiveness of liquid …

Background Tumour mutation burden (TMB), defined as the number of somatic mutations
per megabase within the sequenced region in the tumour sample, has been used as a …

Cervical cancer remains one of the most common cancers in women around the world
however therapeutic options in the advanced and recurrent setting are limited. Immune …

Understanding the tumor microenvironment is important to efficiently identify appropriate
patients for immunotherapies in a variety of cancers. Here, we presented the tumor …

Small cell carcinoma of the ovary, hypercalcemic type (SCCOHT) is an aggressive
malignancy that occurs in young women, is characterized by recurrent loss-of-function …

PD‐L1 and tumor mutation burden (TMB) are the most widely used immunotherapy
biomarkers to identify populations who would attain clinical benefit, with the higher values …

Simple Summary Cancer remains a major cause of morbidity and mortality for millions of
people across the globe. While immunotherapy using immune-checkpoint inhibitors (ICIs) is …

Background Extrahepatic cholangiocarcinoma (ECC) is classified into two subtypes based
on anatomic origin: distal extrahepatic (DECC) and perihilar (PHCC) cholangiocarcinoma …

Background PD-L1 expression and tumour mutational burden (TMB) are both associated
with the responses of multiple tumours to immune checkpoint inhibitor (ICI) therapy …